GlassScriptPhysician profile
Patrick Joseph Anderson
NPI 1508852740
$5,340.00
in general payments reported to CMS, 2019-2025
25 companies · $2,336 in 2025
The $2,336 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.73 · 2022: $57.51 · 2023: $218 · 2024: $2,692 · 2025: $2,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,229 · Education: $16.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,229.06 |
| Education | $16.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,473.07 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $657.00 | 2024-2025 | Sotyktu |
| Janssen Biotech, INC. | $618.44 | 2024-2025 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $418.74 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $263.67 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $243.47 | 2024-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $218.54 | 2024 | Zoryve |
| Incyte Corporation | $207.94 | 2025 | Opzelura, Opzelura |
| Lilly USA, LLC | $207.60 | 2024-2025 | Ebglyss, Taltz |
| Amgen INC. | $198.69 | 2024-2025 | Otezla, Otezla |
| Ucb, INC. | $180.59 | 2024-2025 | Bimzelx |
| Verrica Pharmaceuticals INC. | $158.76 | 2024 | Ycanth |
| Janssen Scientific Affairs, LLC | $101.04 | 2024 | Tremfya |
| Leo Pharma INC. | $77.96 | 2025 | Anzupgo, Adbry |
| Galderma Laboratories, L.P. | $48.87 | 2025 | Nemluvio, Aklief |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $44.62 | 2022 | |
| Phadia US INC. | $40.78 | 2021-2023 | Immunocap |
| Sun Pharmaceutical Industries INC. | $40.58 | 2024-2025 | |
| Dermavant Sciences, INC. | $29.76 | 2024 | Vtama |
| Glaxosmithkline, LLC. | $23.57 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.46 | 2024 | Spevigo |
| Sanofi Pasteur INC. | $19.84 | 2023 | |
| Almirall LLC | $19.44 | 2024 | Klisyri |
| Journey Medical Corporation | $17.53 | 2025 | |
| Organon LLC | $9.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.